Malaria Clinical Trial
Official title:
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
Verified date | October 2006 |
Source | Heidelberg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Burkina Faso: Ministry of Health |
Study type | Interventional |
Design: Single-centre
Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the
efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the
rural and the urban study area of the Centre de Recherche en Santé de Nouna (CRSN).
Population: Children aged 6-59 months with uncomplicated falciparum malaria (axillary
temperature ≥ 37.5°C + ≥ 2.000 P. falciparum asexual parasites per µl blood) from the health
centre situated in the villages of Bagala, Bourasso and Kemena and from Nouna town hospital
outpatient department.
Sample size: N=120
Treatment: All children will receive a total dose of 25 mg/kg oral AQ over a period of three
days (first and second day: 10mg/kg, third day: 5mg/kg).
Statistical procedures: The primary analysis parameter is the proportion of clinical
failures on day 14. Secondary parameters are the rate of clinical failures on day 28 (with
and without PCR correction), the rate of early clinical failures, the rate of late
parasitological failures (day 14 and day 28), and the rate of adverse events. Data will be
analysed in the overall group of study children and for rural (n=50) and urban (n=50) study
children separately.
Study duration and dates: The study will be implemented in September-December 2005.
Status | Completed |
Enrollment | 120 |
Est. completion date | November 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 59 Months |
Eligibility |
Inclusion Criteria: - Age 6-59 months - Uncomplicated falciparum malaria (axillary temperature = 37.5°C and = 2.000 P. falciparum asexual parasites per µl blood) - Written informed consent given by the parents/caretakers Exclusion Criteria: - Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin < 7 g/dl or haematocrit < 21%) - Any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition) - Malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Burkina Faso | Centre de Recherche en Santé de Nouna (CRSN) | Nouna |
Lead Sponsor | Collaborator |
---|---|
Heidelberg University | Centre de Recherche en Sante de Nouna, Burkina Faso |
Burkina Faso,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total clinical failure rate on day 14. | |||
Primary | Clinical failure rate on day 14 in rural study area. | |||
Primary | Clinical failure rate on day 14 in urban study area. | |||
Secondary | Total clinical failure rate on day 28. | |||
Secondary | Clinical failure rate on day 28 in rural study area. | |||
Secondary | Clinical failure rate on day 28 in urban study area. | |||
Secondary | Total early clinical failure rate. | |||
Secondary | Early clinical failure rate in rural study area. | |||
Secondary | Early clinical failure rate in urban study area. | |||
Secondary | Total late parasitological failure rate on day 14 and 28. | |||
Secondary | Late parasitological failure rate on day 14 and 28 in rural study area. | |||
Secondary | Late parasitological failure rate on day 14 and 28 in urban study area. | |||
Secondary | Incidence of observed and self-reported adverse events over the 28 days observation period | |||
Secondary | Monitoring of concomitant drug intake |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |